Clinical Investigation of the Multi4 System

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

NCT06686381 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer

NCT02735512 ·Status: TERMINATED

Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer Patients

NCT05739968 ·Status: RECRUITING ·Phase: NA

A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology

NCT06662071 ·Status: RECRUITING

Outcome of Radiation Therapy in Urinary Bladder Squampus Cell Carcinoma

NCT04815629 ·Status: UNKNOWN

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

NCT01050504 ·Status: RECRUITING

First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma

NCT03324282 ·Status: TERMINATED ·Phase: PHASE2

Bio Clinical Collection of Urothelial Carcinoma

NCT04970472 ·Status: RECRUITING

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

NCT06178601 ·Status: RECRUITING ·Phase: PHASE2

Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder

NCT03529890 ·Status: UNKNOWN ·Phase: PHASE2

Drug Screening Using IMD in Bladder Cancer

NCT06204614 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

NCT03179943 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Efficacy and Safety of UGN-101 in Recurrent Patients

NCT04006691 ·Status: WITHDRAWN ·Phase: PHASE3

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

NCT06133517 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

NCT00234039 ·Status: COMPLETED ·Phase: PHASE2

Quality of Life and Symptom Management in Patients With Bladder Cancer

NCT00772018 ·Status: COMPLETED

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

NCT07129993 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

NCT06331299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

NCT07225127 ·Status: RECRUITING

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

NCT06862219 ·Status: RECRUITING ·Phase: PHASE4

Bladder Cancer Patient-Reported Outcomes

NCT01090388 ·Status: COMPLETED

Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma

NCT04812145 ·Status: UNKNOWN

Trimodality Treatment in Bladder Cancer

NCT06395701 ·Status: COMPLETED

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

NCT04963153 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT05136898 ·Status: COMPLETED ·Phase: PHASE3